Acute Myeloid Leukemia
Also written as AML.
An extended-release preparation of cytarabine leukemia [particularly acute myeloid leukemia (AML)]\n(DepoCyt e) has a longer half-life and is more effective that can occur when the peripheral blast cell count is\nthan other formulations.
What our notes say
- An extended-release preparation of cytarabine leukemia [particularly acute myeloid leukemia (AML)]\n(DepoCyt e) has a longer half-life and is more effective that can occur when the peripheral blast cell count is\nthan other formulations. (Harrisons Pulmonary and Critical Care Medicine)
- DBA is a cancer predisposition syndrome because of the higher risk of myelodysplastic syndrome, acute myeloid leukemia, colon carcinoma, osteogenic sarcoma, and female genital cancers.\n (Anemia of Inadequate production)
- Prognosis: There is risk of developing acute myeloid leukemia. (BABY NELSON PEADS)
- Abortions, recurrent mid-trimester, 531, 552 Acute myeloid leukemia (AML), 482 Acute urate nephropathy, 381 (Harrisons Pulmonary and Critical Care Medicine)
- Hematological: Acute myeloid leukemia (20 times more common). (BABY NELSON PEADS)
Study material on Acute Myeloid Leukemia
Practice questions on Acute Myeloid Leukemia
Characteristic immunophenotype of acute myeloid leukemia?
- CD19+, CD20+, CD10+
- CD3+, CD5+, CD7+
- CD56+, CD16+, CD57+
- CD34+, CD117+, MPO+
- CD138+, CD38+, CD56+
Answer: D. MPO positivity confirms myeloid lineage; CD34/CD117 mark blast/progenitor cells.
Characteristic immunophenotype of acute myeloid leukemia (AML)?
- CD19+, CD20+, CD10+
- CD3+, CD5+, CD7+
- CD34+, CD117+, MPO+
- CD56+, CD16+, CD57+
- CD138+, CD38+, CD56+
Answer: C. AML blasts express myeloid markers: CD117 (c-kit), CD34 (stem cell), and myeloperoxidase (MPO).